Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
-
Published:2024-04
Issue:
Volume:Volume 17
Page:927-933
-
ISSN:1179-1594
-
Container-title:Risk Management and Healthcare Policy
-
language:en
-
Short-container-title:RMHP
Author:
Li Lan-Fang,
Qi RanORCID,
Wei Tian-Tian,
Feng Lei,
Zhang Xin,
Liu QiaoORCID
Publisher
Informa UK Limited
Reference34 articles.
1. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
2. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
3. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
4. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
5. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020